Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Novel Desensitization Kidney Transplantation

Phase 1

Recruiting

Conditions: Kidney Transplantation
End Stage Kidney Disease (ESRD)

Interventions: Drug: Belatacept Injection

First Posted Date: 2022-04-26

Last Posted Date: 2024-06-04

Lead Sponsor: University of Chicago

Target Recruit Count: 5

Registration Number: NCT05345717

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Voice-Activated Technology to Improve Mobility & Reduce Health Disparities (EngAGE)

Phase 2

Recruiting

Conditions: Frailty

Interventions: Behavioral: Enhanced Engagement
Behavioral: Standard Engagement

First Posted Date: 2022-04-20

Last Posted Date: 2024-11-25

Lead Sponsor: University of Chicago

Target Recruit Count: 248

Registration Number: NCT05337514

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Oxalate and Citrate

Not Applicable

Recruiting

Conditions: Kidney Stone
Normal Controls

Interventions: Other: Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic

First Posted Date: 2022-04-19

Last Posted Date: 2024-06-21

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT05334979

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Babies' Expectations About Racial Interactions

Not Applicable

Completed

Conditions: Infant Behavior

Interventions: Other: Basic Science

First Posted Date: 2022-04-12

Last Posted Date: 2024-04-24

Lead Sponsor: University of Chicago

Target Recruit Count: 128

Registration Number: NCT05324007

Locations: 🇺🇸
Infant Learning and Development Laboratory at University of Chicago, Chicago, Illinois, United States

HF Patients With LVADs Being Treated With SGLT2i

Phase 4

Recruiting

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Other: No SGLT2i
Drug: SGLT2i

First Posted Date: 2022-03-15

Last Posted Date: 2023-12-19

Lead Sponsor: University of Chicago

Target Recruit Count: 44

Registration Number: NCT05278962

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Phase 1

Active, not recruiting

Conditions: Prostate Cancer Metastatic
Prostate Cancer
Prostate Adenocarcinoma
Prostate Neoplasm

Interventions: Drug: Abiraterone Oral Tablet
Drug: Prednisone tablet
Other: Drug Dairy/Log
Drug: Low-fat meal

First Posted Date: 2022-03-11

Last Posted Date: 2024-01-29

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT05276492

Locations: 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Recruiting

Conditions: Liver Diseases

First Posted Date: 2022-03-03

Last Posted Date: 2024-11-14

Lead Sponsor: University of Chicago

Target Recruit Count: 1200

Registration Number: NCT05264051

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Prescribed Sternal Precautions vs. Self-Guided Restrictive Care (PEEERC)

Not Applicable

Recruiting

Conditions: Heart Diseases
Surgery
Cardiac Valve Disease
Heart Failure

Interventions: Other: Self Managed Care

First Posted Date: 2022-01-25

Last Posted Date: 2024-10-14

Lead Sponsor: University of Chicago

Target Recruit Count: 64

Registration Number: NCT05206929

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Diabetic Fibular Nail Study

Not Applicable

Terminated

Conditions: Ankle Fractures

Interventions: Procedure: Open reduction and internal fixation
Procedure: Fibular intramedullary nail

First Posted Date: 2022-01-24

Last Posted Date: 2024-10-16

Lead Sponsor: University of Chicago

Target Recruit Count: 2

Registration Number: NCT05204485

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Phase 1

Recruiting

Conditions: Colorectal Adenocarcinoma
Advanced Colorectal Carcinoma
Colorectal Cancer
Colorectal Cancer Metastatic
Advanced Colorectal Adenocarcinoma

Interventions: Drug: VS-6766/avutometinib
Drug: Cetuximab
Other: Pill Diary

First Posted Date: 2022-01-20

Last Posted Date: 2024-05-02

Lead Sponsor: University of Chicago

Target Recruit Count: 53

Registration Number: NCT05200442

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy